The FDA has approved a new medication called brepocitinib, marketed as Lisraya, developed by Roivant and its subsidiary Priovant, for treating dermatomyositis, a rare autoimmune disease causing muscle weakness and skin rashes. Lisraya is a once-daily pill that offers an alternative to the current standard of care, which involves high doses of steroids and other immune-suppressing drugs. Dermatomyositis affects an estimated 40,000 to 70,000 individuals in the U.S.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/08/27/fda-approves-roivant-therapy-for-rare-autoimmune-disease/
